All treatment decisions are based on individual medical evaluations.*
In the UK, Wegovy (semaglutide 2.4 mg weekly) is licensed specifically for weight management in adults with obesity or overweight with weight-related comorbidities, subject to NICE criteria (TA875)
Meticulously planned to deliver maximum value, the project represents a strategic platform for forward-thinking investorsan ecosystem where opportunity, innovation, and prosperity intersect
Independent testing and quality ratings Marketing claims mean nothing without verification
The market potential is enormous, given that MASLD affects roughly 30% of adults globally
This doesnt require a separate medication to address, but it does mean that sleep quality, stress management, and psychological support during treatment arent optional extras